Next Article in Journal
Validity and Reliability of the Helkimo Clinical Dysfunction Index for the Diagnosis of Temporomandibular Disorders
Previous Article in Journal
Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake
Previous Article in Special Issue
Role of Endoscopic Ultrasound in the Diagnosis of Pancreatic Neuroendocrine Neoplasms
Review

Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment

1
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2
Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
3
Keio Cancer Center, Genomic Units, Keio University School of Medicine 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Christian Jenssen
Diagnostics 2021, 11(3), 469; https://doi.org/10.3390/diagnostics11030469
Received: 26 January 2021 / Revised: 27 February 2021 / Accepted: 27 February 2021 / Published: 8 March 2021
(This article belongs to the Special Issue The Advanced Role of Diagnostic Endoscopic Ultrasonography)
Pancreatic cancer is the most lethal solid malignancy, and the number of patients with pancreatic cancer is increasing. Systemic chemotherapies are often ineffective for such patients, and there is an urgent need for personalized medicine. Unlike other types of cancer, personalized treatments for pancreatic cancer are still in development. Consequently, pancreatic cancer is less sensitive to anticancer drugs and is often refractory to common treatments. Therefore, advances in personalized medicine for pancreatic cancer are necessary. This review examined advances in personalized medicine for pancreatic cancer, including the use of endoscopic ultrasound (EUS)-guided sampling. EUS-guided sampling is widely used for diagnosing pancreatic tumors and is expected to be applied to sampled tissues. Additionally, there has been an increase in clinical research using EUS-guided sampling. The combination of precision medicine using genomic testing and pharmacological profiles based on high-throughput drug sensitivity testing using patient-derived organoids is expected to revolutionize pancreatic cancer treatment. View Full-Text
Keywords: EUS-guided sampling; pancreatic cancer; patient-derived organoid; precision medicine EUS-guided sampling; pancreatic cancer; patient-derived organoid; precision medicine
Show Figures

Graphical abstract

MDPI and ACS Style

Iwasaki, E.; Fukuhara, S.; Horibe, M.; Kawasaki, S.; Seino, T.; Takimoto, Y.; Tamagawa, H.; Machida, Y.; Kayashima, A.; Noda, M.; Hayashi, H.; Kanai, T. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics 2021, 11, 469. https://doi.org/10.3390/diagnostics11030469

AMA Style

Iwasaki E, Fukuhara S, Horibe M, Kawasaki S, Seino T, Takimoto Y, Tamagawa H, Machida Y, Kayashima A, Noda M, Hayashi H, Kanai T. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics. 2021; 11(3):469. https://doi.org/10.3390/diagnostics11030469

Chicago/Turabian Style

Iwasaki, Eisuke, Seiichiro Fukuhara, Masayasu Horibe, Shintaro Kawasaki, Takashi Seino, Yoichi Takimoto, Hiroki Tamagawa, Yujiro Machida, Atsuto Kayashima, Marin Noda, Hideyuki Hayashi, and Takanori Kanai. 2021. "Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment" Diagnostics 11, no. 3: 469. https://doi.org/10.3390/diagnostics11030469

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop